.

Deeper Knowledge, Faster

  • Analyze global market entry opportunities
  • Identify first generic entrants
  • Obtain formulation and manufacturing information

Upgrade to enjoy subscriber-only features like email alerts and data export. See the Plans and Pricing

Serving leading biopharmaceutical companies globally:

Queensland Health
Novartis
Accenture
Cantor Fitzgerald
Cerilliant
US Army
Fish and Richardson
Fuji
Julphar
Argus Health

Generated: December 16, 2017

DrugPatentWatch Database Preview

Details for Patent: RE39030

« Back to Dashboard

Which drugs does patent RE39030 protect, and when does it expire?


Patent RE39030 protects PROZAC WEEKLY and is included in one NDA.

This patent has fifty-eight patent family members in forty-five countries.

Summary for Patent: RE39030

Title:Fluoxetine enteric pellets and methods for their preparation and use
Abstract:A superior enteric formulation of the antidepressant drug, fluoxetine, is in the form of enteric pellets of which the enteric layer comprises hydroxypropylmethylcellulose acetate succinate.
Inventor(s): Anderson; Neil Robert (West Lafayette, IN), Harrison; Roger Garrick (Zionsville, IN), Lynch; Daniel Frederick (Indianapolis, IN), Oren; Peter Lloyd (Fishers, IN)
Assignee: Eli Lilly and Company (Indianapolis, IN)
Application Number:10/058,891
Patent Claim Types:
see list of patent claims
Composition; Process; Device; Formulation; Dosage form; Use;

Applicant Tradename Generic Name Dosage NDA Approval Date TE Type RLD RS Patent No. Patent Expiration Product Substance Delist Req. Patented / Exclusive Use Patent Submitted
LillyPROZAC WEEKLYfluoxetine hydrochlorideCAPSULE, DELAYED REL PELLETS;ORAL021235-001Feb 26, 2001ABRXYesYes► Subscribe► SubscribeYMETHOD OF TREATING PEOPLE SUFFERING FROM DEPRESSION► Subscribe
LillyPROZAC WEEKLYfluoxetine hydrochlorideCAPSULE, DELAYED REL PELLETS;ORAL021235-001Feb 26, 2001ABRXYesYes► Subscribe► SubscribeYMETHOD OF TREATING PEOPLE SUFFERING FROM DEPRESSION WITHOUT AN INCREASE IN NAUSEA► Subscribe
This preview shows a limited data set
Subscribe for full access, or try a Trial

Export unavailable in trial.
Subscribe for complete access.

Non-Orange Book Patents for Patent: RE39030

For Orange Book-listed patents (shown in the main table above) generic applications must certify that the listed patents are expired, invalid, or will not be infringed by generic entry.

The non-Orange Book patents listed below do not require formal certifications, so they do not automatically impede generic entry. Instead, they represent potential opportunities for branded firms to block generic entry through patent infringment challenges.

Patent No. Title Estimated Patent Expiration
5,910,319 Fluoxetine enteric pellets and methods for their preparation and use► Subscribe
5,985,322 Method for the treatment of CNS disorders► Subscribe
This preview shows a limited data set
Subscribe for full access, or try a Trial

The estimated expiration dates shown above are derived by simply adding 20 years to the priority date.
Because of the complexity of determining patent expiration dates it is advisable to have patent counsel verify freedom to operate.

Export unavailable in trial.
Subscribe for complete access.

International Patent Family for Patent: RE39030

Country Document Number Estimated Expiration Supplementary Protection Certificate SPC Country SPC Expiration
Argentina011728► Subscribe
Austria408068► Subscribe
AustriaA93198► Subscribe
Australia6904898► Subscribe
Australia726690► Subscribe
Belgium1011925► Subscribe
Brazil9801989► Subscribe
Canada2234826► Subscribe
Switzerland693018► Subscribe
China1161109► Subscribe
This preview shows a limited data set
Subscribe for full access, or try a Trial

The estimated expiration dates shown above are derived by simply adding 20 years to the priority date.
Due to the complexity of determining patent expirations even in a single country, compounded by the diversity of global patent laws, it is advisable to have patent counsel verify freedom to operate.

Export unavailable in trial.
Subscribe for complete access.

For more information try a trial or see the plans and pricing

Serving leading biopharmaceutical companies globally:

Cantor Fitzgerald
Covington
Merck
Deloitte
McKesson
Novartis
Federal Trade Commission
Accenture
McKinsey
US Department of Justice

Drugs may be covered by multiple patents or regulatory protections. All trademarks and applicant names are the property of their respective owners or licensors. Although great care is taken in the proper and correct provision of this service, thinkBiotech LLC does not accept any responsibility for possible consequences of errors or omissions in the provided data. The data presented herein is for information purposes only. There is no warranty that the data contained herein is error free. thinkBiotech performs no independent verifification of facts as provided by public sources nor are attempts made to provide legal or investing advice. Any reliance on data provided herein is done solely at the discretion of the user. Users of this service are advised to seek professional advice and independent confirmation before considering acting on any of the provided information. thinkBiotech LLC reserves the right to amend, extend or withdraw any part or all of the offered service without notice.

Copyright 2002-2017 thinkBiotech LLC
ISSN: 2162-2639

Secure SSL Encrypted
Privacy and Cookies
Terms & Conditions

Follow DrugPatentWatch:

botpot